Innoxus, a medical aesthetic device startup has secured KRW14.2 billion in Series A funding. The round was led by Altos Ventures, a venture capital firm known for backing high-growth Korean startups.
This investment comes as the company continues to demonstrate rapid growth in the competitive global beauty tech market. A portion of the funding was structured as a secondary transaction, acquiring shares from Tale Ventures, the seed investor that first discovered the company.
Founded in February 2022, Innoxus is an innovative medical device company led by CEO Shim Jae-yong, a medical doctor and graduate of Seoul Science High School and Seoul National University College of Medicine. The company’s flagship product, Alltite, is a lifting device that applies Dielectric Heating Technology (DLTD)—originally used for cancer treatment and rehabilitation—to aesthetic medicine for the first time. This technology addresses the limitations of existing lifting devices, offering a differentiated solution in the market. The product has already proven its market viability, securing export contracts for over 300 units in Japan, Hong Kong, and Brazil prior to its domestic launch, and selling over 200 units within just 10 months of release.
Innoxus plans to use the secured capital to accelerate its expansion into key global markets, including North America, Europe, and Asia.
